Major Pharmaceutical Companies Lilly and Boehringer Stop Investments
16 Articles
16 Articles
The US pharmaceutical company Eli Lilly is returning its planned billion-dollar investment to a new production site in Alzey, Rhineland-Palatinate.
The U.S. pharmaceutical company Lilly halved its planned investment in Rhineland-Palatinate. Boehringer Ingelheim is also cutting back on plans. Both companies also refer to the government's policy as a reason.
With a major reform of the statutory health insurance the Federal Government wants to save costs. Therefore, pharmaceutical companies rethink their investments. Two large companies now have bad news for the location Germany.
US pharmaceuticalist Eli Lilly reduces the investment for the planned production site to a minimum and refers to the Federal Government's savings plans. A German company also stops investments.
It is another negative news from the pharmaceutical industry: Due to the Federal Government's savings plans, the US Group wants to drastically reduce a major investment in Rhineland-Palatinate. Based in Indianapolis, the US pharmaceutical company Eli Lilly wants to significantly reduce a planned billion-dollar investment in a new location in Alzey, Rhineland-Palatinate, due to the Federal Government's savings plans in the healthcare sector. Head…
The family business does not want to spend almost a billion euros as planned in Germany. Due to the planned health insurance reform, it lacks reliability and attractive market conditions, says Boehringer's head of Germany.
Coverage Details
Bias Distribution
- 38% of the sources are Center, 37% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
